Acuity Inc (AYI) Q2 2026 Earnings Call Transcript

Why It Matters

The revenue and margin contraction underscores heightened geopolitical risk in China, while the restructuring plan signals a strategic shift toward higher‑margin, recurring services to restore profitability.

Key Takeaways

• Revenue fell 12% YoY to $102.2M.
• Product sales slumped 26% amid China tariffs.
• Service revenue grew 4%, supporting recurring income.
• Gross margin dropped to 23.5% from 36.1%.
• Guidance cut; revenue $440‑450M, EBITDA $22‑25M.

Pulse Analysis

Accuray’s second‑quarter results highlight the vulnerability of medical‑device manufacturers to geopolitical headwinds, especially in China. Tariff escalations and a protracted licensing process throttled product shipments, driving a 26% decline in product revenue and eroding gross margins by over 12 percentage points. While the broader global hospital capital‑expenditure environment remains stable, the company’s exposure to a single, high‑growth market amplified earnings volatility, prompting a cautious outlook for the remainder of fiscal 2026.

In response, Accuray launched a comprehensive transformation plan centered on rightsizing its cost base and expanding its service portfolio. A 15% workforce reduction, facility consolidations, and outsourced non‑core functions are expected to generate $25 million of annualized operating profit improvements, with $12 million already earmarked for this year. The shift toward higher‑margin, recurring service revenue—already up 4%—aims to smooth earnings cycles and improve cash conversion, while structured distributor programs and pricing optimization are designed to protect margins against future tariff shocks.

The revised full‑year guidance—revenue now projected at $440‑$450 million and adjusted EBITDA at $22‑$25 million—reflects a realistic recalibration of expectations amid ongoing uncertainty. Investors will watch the execution of the restructuring roadmap and the pace of service‑revenue growth as leading indicators of the company’s ability to regain profitability. If Accuray can successfully transition to a service‑centric model while mitigating China‑related risks, it could re‑establish a more resilient earnings trajectory and deliver sustainable shareholder value.